

Resource Summary Report

Generated by [dkNET](#) on Sep 9, 2026

HER4/ErbB4 (111B2) Rabbit mAb

RRID:AB_2099883

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4795, RRID:AB_2099883

Antibody Information

URL: http://antibodyregistry.org/AB_2099883

Proper Citation: Cell Signaling Technology Cat# 4795, RRID:AB_2099883

Target Antigen: HER4/ErbB4 (111B2) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10698607, AB_2099883.

Antibody Name: HER4/ErbB4 (111B2) Rabbit mAb

Description: This monoclonal targets HER4/ErbB4 (111B2) Rabbit mAb

Target Organism: h, m, mouse, human

Antibody ID: AB_2099883

Vendor: Cell Signaling Technology

Catalog Number: 4795

Record Creation Time: 20231110T070144+0000

Record Last Update: 20260829T171248+0000

Ratings and Alerts

No rating or validation information has been found for HER4/ErbB4 (111B2) Rabbit mAb.

No alerts have been found for HER4/ErbB4 (111B2) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. *Oncogene*, 45(31), 3244.

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. *Cancer research*, 86(6), 1467.

Li C, et al. (2025) Liver-breast communication of adipocyte-oriented exosomes drives primary mammary cancer progression. *Cell metabolism*.

Trenker R, et al. (2024) Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation. *eLife*, 12.

Huang J, et al. (2024) NRG1-ErbB4 signaling in the medial amygdala controls mating motivation in adult male mice. *Cell reports*, 43(3), 113905.

Albert V, et al. (2024) HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. *International journal of molecular sciences*, 25(13).

Bahnassy S, et al. (2023) Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer. *Endocrinology*, 164(12).

Bahnassy S, et al. (2023) Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer. *bioRxiv : the preprint server for biology*.

Wurm AA, et al. (2023) Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity. *Cell reports. Medicine*, 4(10), 101200.

Spahic H, et al. (2022) Dysregulation of ErbB4 Signaling Pathway in the Dorsal Hippocampus after Neonatal Hypoxia-Ischemia and Late Deficits in PV+ Interneurons, Synaptic Plasticity and Working Memory. *International journal of molecular sciences*, 24(1).

De Bacco F, et al. (2021) ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

Cell reports, 36(4), 109455.

Iniguez AB, et al. (2018) Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer cell, 34(6), 922.

Cooper MA, et al. (2014) Ablation of ErbB4 from excitatory neurons leads to reduced dendritic spine density in mouse prefrontal cortex. The Journal of comparative neurology, 522(14), 3351.